The Trump administration is using voluntary agreements with healthcare, food and pharmaceutical companies to pursue synthetic-dye removal, reduced prior authorization, nutrition education and lower prescription prices. Supporters say the approach fits Republicans' anti-regulatory stance and allows faster action than federal rulemaking, while critics cite weak enforcement, limited transparency and uncertain results. Food-dye commitments have missed or extended deadlines; insurers reported an approximately 11% reduction in medical-service prior authorization as of July despite a pledge targeting 80% of requirements across 80% of diseases and injuries by January 2026; and drug-pricing agreements with 17 companies mainly cover Medicaid enrollees and cash-paying consumers using TrumpRx. Bloomberg also reported that the administration planned to announce additional agreements with several undisclosed midsized biotech companies, under which state Medicaid programs could voluntarily receive outpatient-drug discounts tied to foreign prices in exchange for exemptions from similar Medicare pilot programs, with tariff relief part of some discussions. The potential savings and final terms remain unclear, and the White House said proposed deals should be considered speculative until officially announced. The initiatives could shape Republicans' health record ahead of the November midterm elections.